Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8501819 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(3 years from now) | |
US9382191 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(3 years from now) | |
US8450375 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(3 years from now) | |
US8501818 | HELSINN | Stabilized compositions of alkylating agents and methods of using same |
Mar, 2026
(3 years from now) | |
US7838564 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(3 years from now) | |
US7872050 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Jul, 2029
(6 years from now) |
Market Authorisation Date: 23 August, 2013
Treatment: Alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy
Dosage: GEL;TOPICAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic